Ilumetri

Tildrakizumab, the active ingredient in Ilumetri, is a interleukin‑23 (IL‑23) inhibitor presented as a solution for subcutaneous injection for subcutaneous use. It is indicated for the treatment of moderate‑to‑severe plaque psoriasis in adult patients.

GNH USA supplies Ilumetri as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for biologic products. These services ensure consistent product integrity from manufacturing to end‑user delivery across global markets.

Ilumetri, an interleukin‑23 inhibitor, is used to manage moderate‑to‑severe plaque psoriasis.

- Moderate-to-severe plaque psoriasis: Reduces skin lesions and improves quality of life in adult patients.

Common Side Effects: - Injection site reactions: redness, swelling, or pain at the injection site. - Upper respiratory infections: mild cold‑like symptoms. - Headache: occasional mild to moderate intensity. - Fatigue: feeling unusually tired. - Nausea: occasional upset stomach. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Severe allergic reactions: anaphylaxis or angioedema. - Serious infections: opportunistic infections such as tuberculosis. - Inflammatory bowel disease exacerbation: worsening of Crohn's disease or ulcerative colitis. - Malignancies: potential increased risk of certain cancers. - Cardiovascular events: rare cases of heart failure or myocardial infarction.

Before starting Ilumetri, clinicians should consider several safety measures. - Screen for active infections: evaluate patients for tuberculosis and other infections before initiation. - Monitor for signs of allergic reaction: observe patients during and after injection for rash, swelling, or breathing difficulty. - Assess cardiovascular risk: use caution in patients with a history of heart disease. - Avoid live vaccines: do not administer live attenuated vaccines during treatment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ilumetri may interact with other therapies; awareness helps manage risk. Major Interactions (Avoid): - Live vaccines: contraindicated during treatment. - Immunosuppressive agents (e.g., azathioprine, methotrexate): increased risk of serious infection. Moderate Interactions (Monitor Closely): - Systemic corticosteroids: monitor for infection. - Antifungal azoles: monitor liver function. - Non‑live vaccines: may have reduced efficacy.